Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Guj Themis Biosyn
Join Channel
Consolidated Standalone

Guj. Themis Biosyn

₹398.5 2.4 | 0.6%

Market Cap ₹2895 Cr.

Stock P/E 52.7

P/B 15.2

Current Price ₹398.5

Book Value ₹ 26.3

Face Value 1

52W High ₹820

Dividend Yield 0.27%

52W Low ₹ 145.8

Edit Ratio

Guj. Themis Biosyn Research see more...

Overview Inc. Year: 1981Industry: Pharmaceuticals & Drugs

Gujarat Themis Biosyn Ltd is engaged in the production of pharmaceuticals and medicinal chemical merchandise. The Company's R&D division makes a speciality on developing fermentation cultures. The Company's products consist of Rifamycin-S, that is an intermediate for Rifampicin for the remedy of tuberculosis (TB), and Lovastatin. It is engaged in manufacturing bulk drugs. The Company's plant is located at Valsad, Gujarat.

Read More..

Guj. Themis Biosyn Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Guj. Themis Biosyn Quarterly Results

#(Fig in Cr.) Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 35 19 29 45 48 28 28 50 40 39
Other Income 1 1 2 1 1 2 1 1 1 1
Total Income 36 19 30 46 49 30 30 51 41 40
Total Expenditure 17 9 16 22 23 16 13 26 23 21
Operating Profit 19 10 15 24 26 14 16 25 18 19
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 18 10 14 24 25 13 16 24 17 18
Provision for Tax 5 2 4 6 6 3 4 6 4 5
Profit After Tax 14 7 10 18 19 10 12 18 13 13
Adjustments 0 -0 0 -0 0 0 0 0 0 0
Profit After Adjustments 14 7 10 18 19 10 12 18 13 13
Adjusted Earnings Per Share 1.9 1 1.3 2.4 2.6 1.4 1.6 2.4 1.7 1.8

Guj. Themis Biosyn Profit & Loss

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 28 30 31 33 36 39 41 85 91 115 149 157
Other Income 0 0 0 0 0 0 2 2 3 4 6 4
Total Income 29 30 32 33 36 39 43 87 94 119 155 162
Total Expenditure 25 24 25 27 30 33 34 53 50 57 75 83
Operating Profit 4 7 6 6 6 6 10 34 44 62 80 78
Interest 1 1 0 0 0 0 0 1 1 1 0 0
Depreciation 2 1 1 1 1 1 1 1 2 2 3 4
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 1 5 5 5 5 5 8 31 41 59 77 75
Provision for Tax 0 0 0 0 1 1 2 8 11 15 19 19
Profit After Tax 1 5 5 5 4 4 6 24 30 44 58 56
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments 1 5 5 5 4 4 6 24 30 44 58 56
Adjusted Earnings Per Share 0.1 0.6 0.6 0.6 0.6 0.5 0.9 3.3 4.2 6 8 7.5

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 30% 21% 31% 18%
Operating Profit CAGR 29% 33% 68% 35%
PAT CAGR 32% 34% 71% 50%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 145% 91% 117% 70%
ROE Average 46% 50% 54% 62%
ROCE Average 62% 66% 66% 75%

Guj. Themis Biosyn Balance Sheet

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds -10 -5 -1 4 8 12 19 42 70 103 149
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 7 6 5 1 1 0 0 3 0 0 0
Other Non-Current Liabilities 0 0 0 0 1 0 1 1 2 2 2
Total Current Liabilities 21 15 10 9 12 8 13 24 26 32 36
Total Liabilities 18 16 15 15 21 20 33 71 98 137 187
Fixed Assets 12 11 10 9 11 11 15 17 19 19 33
Other Non-Current Assets 2 2 2 2 3 2 10 18 6 25 73
Total Current Assets 4 3 3 3 8 8 8 36 73 93 81
Total Assets 18 16 15 15 21 20 33 71 98 137 187

Guj. Themis Biosyn Cash Flow

#(Fig in Cr.) Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 1 0 1 0 0 0 1 1 1 4 0
Cash Flow from Operating Activities 0 4 3 4 3 6 1 1 11 40 40
Cash Flow from Investing Activities -3 -0 -0 -1 -3 -1 -6 -3 -2 -30 -20
Cash Flow from Financing Activities 2 -3 -3 -3 -0 -4 5 2 -5 -14 -13
Net Cash Inflow / Outflow -0 1 -1 -0 0 1 0 -0 3 -4 6
Closing Cash & Cash Equivalent 0 1 0 0 0 1 1 1 4 0 6

Guj. Themis Biosyn Ratios

# Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 0.15 0.62 0.63 0.64 0.6 0.53 0.88 3.26 4.15 6.01 7.98
CEPS(Rs) 0.43 0.82 0.82 0.8 0.76 0.69 1.05 3.45 4.39 6.31 8.33
DPS(Rs) 0 0 0 0 0 0 0 0.33 0 2.2 1.08
Book NAV/Share(Rs) -1.36 -0.74 -0.11 0.53 1.13 1.67 2.55 5.81 9.63 14.22 20.53
Core EBITDA Margin(%) 12.64 21.54 19.94 18.5 16.95 16.08 17.93 37.4 44.53 50.54 49.82
EBIT Margin(%) 6.43 17.34 15.84 15.35 14.83 13.55 20.35 37.8 46.23 52.12 52.13
Pre Tax Margin(%) 3.72 14.97 14.61 14.19 13.69 12.47 19.96 36.72 45.14 51.4 52
PAT Margin (%) 3.72 14.97 14.61 14.19 12.26 9.97 15.61 27.81 33.32 37.98 38.91
Cash Profit Margin (%) 10.85 19.81 18.99 17.86 15.4 12.93 18.59 29.41 35.24 39.93 40.64
ROA(%) 6.02 26.54 29.88 31.5 24.25 18.45 24.07 45.62 35.65 37.08 35.81
ROE(%) 0 0 0 302.71 72.63 38.06 41.85 77.99 53.82 50.35 45.92
ROCE(%) 0 209.07 113.74 80.38 54.67 42.22 44.88 85.96 67.89 67.91 61.53
Receivable days 34.72 24.84 20.96 25.38 46.8 45.67 37.88 55.8 70.42 63.29 52.71
Inventory Days 6.04 4.13 4.57 4.19 4.73 4.57 3.55 13.65 24.34 28.06 32.13
Payable days 1511.07 6998.5 6783.88 6332.41 1554.64 1079.66 1966.91 215.31 132.5 115.1 114.42
PER(x) 10.85 3.13 11.98 15.94 17.21 15.67 8.91 5.96 9.8 13.57 17.2
Price/Book(x) -1.18 -2.66 -70.11 19.2 9.18 5 3.08 3.35 4.23 5.73 6.69
Dividend Yield(%) 0 0 0 0 0 0 0 1.7 0 2.7 0.79
EV/Net Sales(x) 0.8 0.73 1.94 2.36 2.21 1.46 1.5 1.73 3 5.05 6.63
EV/Core EBITDA(x) 5.83 3.3 9.58 12.4 12.31 8.85 6.41 4.39 6.22 9.33 12.31
Net Sales Growth(%) 225.7 6.57 4 3.77 9.4 8.71 5.8 107.37 6.39 26.82 29.71
EBIT Growth(%) -31.99 183.55 -4.95 0.51 5.72 -0.71 58.95 285.2 30.09 42.99 29.74
PAT Growth(%) -32.58 323.08 1.51 0.77 -5.44 -11.66 65.73 269.4 27.48 44.55 32.88
EPS Growth(%) -46.17 323.08 1.51 0.77 -5.44 -11.66 65.73 269.39 27.47 44.55 32.88
Debt/Equity(x) -1.16 -1.65 -7.74 0.86 0.49 0.05 0.32 0.19 0.04 0 0
Current Ratio(x) 0.19 0.22 0.35 0.34 0.69 0.99 0.63 1.49 2.84 2.93 2.28
Quick Ratio(x) 0.18 0.19 0.32 0.32 0.65 0.93 0.6 1.24 2.6 2.57 1.87
Interest Cover(x) 2.37 7.33 12.86 13.26 12.96 12.59 52.71 34.85 42.66 72.31 386.97
Total Debt/Mcap(x) 0.98 0.62 0.11 0.05 0.05 0.01 0.11 0.06 0.01 0 0

Guj. Themis Biosyn Shareholding Pattern

# Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
Promoter 74.99 74.99 74.99 74.99 74.99 74.99 74.99 74.99 70.86 70.86
FII 0 0 0 0 0.01 0.01 0.01 0.01 0.87 1.05
DII 0.31 0.31 0.31 0.03 0.03 0.03 0.03 0.03 0.04 0.82
Public 24.7 24.7 24.69 24.97 24.96 24.96 24.96 24.96 28.23 27.26
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

Pros

  • Company has delivered good profit growth of 70% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 50%
  • Debtor days have improved from 115.1 to 114.42days.
  • Company is almost debt free.

Cons

  • Stock is trading at 15.2 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Guj. Themis Biosyn News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!